Investment Updates | Q2 2025
New Strategic Engagements:
GTI Capital (Hong Kong)
Discretionary participation in AI index infrastructure & RWA platform.
AurumX Biotech
JV equity execution phase
underway
Blockridge Infrastructure
Token model & ESG structuring in progress
Why Xenous?
A Purpose-Built Investment Vehicle
Regulatory
Credibility
U.S. listing structure, SEC disclosures, and robust reporting
Global Investment Gateways
Seamless access to structured capital opportunities across the U.S., China, and Southeast Asia
Zero Operational Overhead
Pure SPV entity with no legacy liabilities or fixed cost base
Privileged Deal
Access
Exclusive pipeline of early-stage, pre-institutional opportunities
Privileged Access.
Structured Capital.
Global Reach.
OTC: XITO | U.S.-Listed | Multi-Million Capitalized SPV
Our Mandate as a Strategic SPV
Xenous is not a traditional operating company — it is a professionally structured SPV created to:
Ring-fence financial risk, separating investments from parent liabilities
Enable high-velocity capital deployment into targeted ventures
Create institutional-grade investment vehicles for global allocators
Maintain U.S. compliance while executing in emerging and regulated APAC markets
Our vehicle is built for financial precision, market discretion, and strategic access to ventures typically unreachable by retail participants.
Joint Venture Portfolio (2025–2026)
Our active investment strategy includes a curated portfolio of structured JV initiatives, designed to provide asymmetric return profiles with institutional safeguards:
AurumX Biotech Alliance — Singapore / Shenzhen
A multi-phase biotech innovation JV focused on advanced cellular therapy, precision diagnostics, and IP licensing.
Structure: 30% equity + convertible note SPV
Objective: Early-stage biotech equity aggregation ahead of public clinical phase
Blockridge Infrastructure Fund — Malaysia / Dubai
A dual-jurisdiction SPV for next-generation renewable energy logistics and AI-integrated cold chain networks.
Structure: 50:50 JV with sovereign-linked energy group
Objective: Tokenize infrastructure yields and facilitate energy credit trading
Capital Markets Roadmap:
OTC to Nasdaq (Target: 2026 Q1)
Xenous Group is undergoing structured transformation for uplisting to the Nasdaq Capital Market, driven by strengthened compliance, increased institutional visibility, and long-term capital strategy alignment.
We are currently engaged with top-tier legal, audit, and IR advisors to fast-track this listing upgrade.
Institutional trading access via regulated platforms
Stronger valuation benchmarks and audit protocols
Enhanced liquidity and governance transparency
Xenous Group is a capital strategy vehicle—not an asset manager, not a fund. We operate under mandate, by invitation, and in alignment with capital partners who value structure, clarity, and discreet performance.
For capital collaboration, private briefings, or structuring proposals, please contact our executive desk.
Access . Precision . Ascent .
About Xenous Group
Xenous Group (OTC: XITO) is a U.S.-listed investment holding company headquartered in Malaysia, operating under a strategic Special Purpose Vehicle (SPV) structure. Founded in 1980 and now fully capitalized with multimillion-dollar liquidity, Xenous serves as a private investment gateway tailored exclusively for institutional and high-net-worth partners.
We specialize in cross-border asset acquisition, joint venture structuring, and real-world asset integration, with a growing presence in high-growth sectors across Greater China and Southeast Asia.
